跳转至内容
Merck
CN

D2763

双氢麦角胺 甲磺酸盐

powder

登录 查看组织和合同定价。

选择尺寸

变更视图

关于此项目

经验公式(希尔记法):
C33H37N5O5 · CH4O3S
化学文摘社编号:
分子量:
679.78
NACRES:
NA.77
PubChem Substance ID:
UNSPSC Code:
12352200
EC Number:
228-235-6
MDL number:
Form:
powder
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助


form

powder

color

white

solubility

methanol: 21 mg/mL, 45% (w/v) aq 2-hydroxypropyl-β-cyclodextrin: 5.45 mg/mL, H2O: insoluble

SMILES string

CS(O)(=O)=O.[H][C@@]12Cc3c[nH]c4cccc(C1C[C@H](CN2C)C(=O)N[C@]5(C)O[C@]6(O)N([C@@H](Cc7ccccc7)C(=O)N8CCC[C@@]68[H])C5=O)c34

InChI

1S/C33H37N5O5.CH4O3S/c1-32(35-29(39)21-15-23-22-10-6-11-24-28(22)20(17-34-24)16-25(23)36(2)18-21)31(41)38-26(14-19-8-4-3-5-9-19)30(40)37-13-7-12-27(37)33(38,42)43-32;1-5(2,3)4/h3-6,8-11,17,21,23,25-27,34,42H,7,12-16,18H2,1-2H3,(H,35,39);1H3,(H,2,3,4)/t21-,23?,25-,26+,27+,32-,33+;/m1./s1

InChI key

ADYPXRFPBQGGAH-WVVAGBSPSA-N

Gene Information

human ... DRD2(1813)

Biochem/physiol Actions

血管羟色胺受体激动剂;α-肾上腺素和多巴胺 D2 受体部分激动剂;血管收缩剂。
Vascular serotonin receptor agonist; vasoconstrictor.


pictograms

Exclamation mark

signalword

Warning

Hazard Classifications

Acute Tox. 4 Dermal - Acute Tox. 4 Inhalation

存储类别

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

dust mask type N95 (US), Eyeshields, Gloves

法规信息

新产品

此项目有



历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

没有发现合适的版本?

如果您需要特殊版本,可通过批号或批次号查找具体证书。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库


相关内容

Product Information Sheet


Nancy E Kelley et al.
Headache, 52(1), 114-128 (2012-01-04)
To review and analyze published reports on the acute treatment of migraine headache with triptans, dihydroergotamine (DHE), and magnesium in emergency department, urgent care, and headache clinic settings. MEDLINE was searched using the terms "migraine" and "emergency," and "therapy" or
D Kellerman et al.
Cephalalgia : an international journal of headache, 32(2), 150-158 (2011-12-17)
Dihydroergotamine (DHE), a proven migraine treatment, currently has product labeling warning against concomitant use of CYP3A4 inhibitors because of potential drug interactions. However, no reported studies of such interactions with DHE administered by any route are available. The pharmacokinetics (PK)
Bruno A Marichal-Cancino et al.
European journal of pharmacology, 692(1-3), 69-77 (2012-07-31)
It has been suggested that during a migraine attack trigeminal nerves release calcitonin gene-related peptide (CGRP), producing central nociception and vasodilatation of cranial arteries, including the extracranial branches of the external carotid artery. Since trigeminal inhibition may prevent this vasodilatation